Mobia Medical Announces Pricing of Initial Public Offering

Mobia Medical, Inc. has announced the pricing of its initial public offering (IPO), aiming to raise approximately $150 million through the sale of 10 million shares of common stock at a price of $15.00 per share. The shares are set to begin trading on the Nasdaq Global Select Market under the ticker symbol "MOBI" on May 8, 2026, with the offering expected to close on May 11, 2026, pending customary closing conditions. The IPO represents a significant milestone for the company as it seeks to expand its reach in the medical device sector.

Based in Austin, Texas, Mobia Medical is a commercial-stage medical device company focused on redefining stroke recovery for survivors facing life-altering motor impairments. The company’s flagship product, the Vivistim® Paired VNS™ System, is the first FDA-approved implantable solution that combines targeted vagus nerve stimulation with functional movement to enhance upper limb function in chronic ischemic stroke survivors. This innovative approach aims to promote neuroplasticity and drive meaningful improvements in motor function, positioning Mobia Medical as a key player in the evolving landscape of stroke rehabilitation.

The strategic rationale behind the IPO is to secure capital that will enable Mobia Medical to accelerate its growth and expand its product offerings. The funds raised will likely be allocated towards research and development, regulatory approvals, and marketing initiatives to further penetrate the medical device market. As the demand for effective stroke recovery solutions continues to rise, driven by an aging population and increasing prevalence of stroke-related disabilities, Mobia Medical is well-positioned to capitalize on this trend.

The medical device sector is experiencing robust growth, with advancements in technology and increasing investment in healthcare innovation. The successful IPO of Mobia Medical underscores the investor interest in companies that are addressing significant healthcare challenges, particularly in the realm of chronic conditions like stroke. As the market for medical devices continues to expand, companies like Mobia Medical that offer unique and clinically validated solutions are likely to attract further investment and attention.

In conclusion, Mobia Medical's IPO marks a pivotal moment for the company and highlights the broader trends within the medical device sector. As the market evolves, the focus on innovative solutions for stroke recovery will likely drive continued interest from investors and stakeholders. The successful execution of this offering may pave the way for future growth opportunities, setting a precedent for other companies in the medical technology space.